国产首款胶质瘤电场治疗产品上市，“癌王”治疗有了新解法

Core Insights - The tumor electric field therapy system developed in China has received approval from the National Medical Products Administration, marking a significant breakthrough in the treatment of glioblastoma, a highly malignant brain tumor, and breaking the long-standing foreign technological monopoly [1][2] Group 1: Product Approval and Clinical Trials - The electric field therapy system is the first of its kind in China and the second globally for glioblastoma treatment, based on a pivotal Phase III clinical trial led by Beijing Tiantan Hospital and involving 11 top medical institutions [1][3] - The trial results indicate that for newly diagnosed glioblastoma patients, the median overall survival (mOS) can be significantly extended from approximately 15 months to 31.11 months when combined with standard surgery and radiochemotherapy [1] Group 2: Treatment Benefits and Accessibility - The non-invasive nature of the treatment allows for home-based therapy, improving patient compliance and quality of life while avoiding the side effects associated with traditional drug treatments [2] - The successful launch of this domestic product is expected to drastically reduce treatment costs, which previously exceeded one million yuan annually for imported products, thereby enhancing accessibility for patients [2] Group 3: Future Developments - A new generation of personalized electric field therapy based on genomics is currently in preclinical research, aiming to further optimize treatment efficacy through tailored approaches [2]